Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow. AML is the most common acute leukemia affecting adults, with about 20,000 new cases diagnosed each year. MDS progresses to AML in approximately 30% of patients. The risk of developing AML depends largely on which MDS subtype you have at the time of diagnosis. Huge breakthroughs have been made in recent years in regard to understanding the genomic landscape for AML and how to best manage this rare cancer. The MDS Foundation is proud to be a patient advocacy ambassador member of the KNOW AML Coalition, a collective of AML patient leaders, professional, and industry representatives. If you are affected or know someone affected by AML, you are not alone. Visit know-aml.com and the MDS Foundation for further in-depth information on AML. Let’s unite and join the global effort to raise the awareness of Acute Myeloid Leukemia on AML World Awareness Day! | 
11°C
